

THURSDAY, OCTOBER 12, 1 – 2:30 PM CT • PLAZA A (LOBBY LEVEL, EAST TOWER)

S2207

The **S2207** kickoff session will provide valuable information to SWOG members who will be enrolling patients to this new trial in large B-cell lymphoma. Join us in person in Chicago or virtually from anywhere.

S2207: Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

STUDY CHAIRS



Jennifer Amengual, MD




Patrick Reagan, MD



Sonali Smith, MD



Alexey Danilov, MD (TM)

Hayder Saeed, MD
(PROs)

S2207 was activated at the end of June. It will enroll patients with large B-cell lymphoma (LBCL) who are considered ineligible for transplant or for CAR T-cell therapy or who have relapsed after these treatments.

This three-arm randomized trial compares a tafasitamab-lenalidomide combination alone to the combination plus tazemetostat or plus zuberutinib.

This S2207 kickoff session will review

- trial background, eligibility criteria, and the treatment plan
 - biospecimen collection
 - patient-reported outcomes
 - patient education materials

The trial's target patient population is treated primarily in the community setting.

Staff at community treatment centers are encouraged to attend.

Our patient advocates have been working with the study team to craft additional patient education materials for the trial. We will share printed copies of these at the S2207 kickoff session.

BRING YOUR QUESTIONS!